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ABSTRACT
Background: The coronavirus disease 2019 (COVID-19) pandemic has caused deaths and short-
ages in medical resources worldwide, making the prediction of patient prognosis and the identi-
fication of risk factors very important. Increasing age is already known as one of the main risk
factors for poor outcomes, but the effect of body mass index (BMI) on COVID-19 outcomes in
older patients has not yet been investigated.
Aim: We aimed to determine the effect of BMI on the severity and mortality of COVID-19
among older patients in South Korea.
Methods: Data from 1272 COVID-19 patients (60 years old) were collected by the Korea
Centers for Disease Control and Prevention. The odds ratios (ORs) of severe infection and death
in the BMI groups were analyzed by logistic regression adjusted for covariates.
Results: The underweight group (BMI<18.5 kg/m2) had a higher OR for death (adjusted OR =
2.23, 95% confidence interval [95% CI] = 1.06–4.52) than the normal weight group (BMI,
18.5–22.9 kg/m2). Overweight (BMI, 23.0–24.9 kg/m2) was associated with lower risks of both
severe infection (adjusted OR = 0.55, 95% CI = 0.31–0.94) and death (adjusted OR = 0.50, 95%
CI = 0.27–0.91).
Conclusions: Underweight was associated with an increased risk of death, and overweight was
related to lower risks of severe infection and death in older COVID-19 patients in Korea.
However, this study was limited by the lack of availability of some information, including smok-
ing status.
KEY MESSAGES
 Underweight is an independent risk factor of death in older COVID-19 patients.
 Overweight patients have a lower risk of death and severe infection than normal-
weight patients.
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Introduction
First discovered in December 2019, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a large number of casualties worldwide. As of
February 2021, 108,246,992 patients had been diag-
nosed with coronavirus disease 2019 (COVID-19), and
2,386,717 had died worldwide [1]. Previous studies
have suggested that risk factors such as older age,
smoking, comorbidities, and obesity are associated with
the severity of COVID-19 [2–5]. Among these risk fac-
tors, obesity is known not only for its risk in the context
of COVID-19 but also for pulmonary infections, such as
aspiration pneumonia and community-acquired pneu-
monia [6,7]. Numerous reports have defined the rela-
tionship between body mass index (BMI) and mortality
due to various diseases. The results showed mostly J-
or U-shaped relationships, indicating increased risks
associated with both obesity and underweight [8–11].
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Some studies identified reverse J-shaped relationships
among older patients [12].
During this unprecedented crisis, many researchers
have attempted to predict the risk of mortality due to
COVID-19 according to BMI based on the background
knowledge described above [13–17]. However, since
the epicentres of the COVID-19 pandemic have mostly
been in Western countries, the majority of results are
from Europe or America. These results have clear limi-
tations regarding their generalizability to Asians
because the prevalence of obesity and distribution of
BMI values differ substantially between Western and
Asian populations. The World Health Organization
(WHO) defines obesity as BMI  30 kg/m2 in Western
populations and 25 kg/m2 in Asian populations
because of the difference in body fat percentage. The
criteria for underweight are the same in both popula-
tions [18,19]. Individuals with a BMI  25 kg/m2 in
America account for approximately 68.8–74% of the
total population, compared to 35% in South Korea.
The percentage of the population classified as under-
weight is also different, accounting for 1.4–1.5% in
America and 4.81% in South Korea [20–23]. This differ-
ence resulted in statistically nonsignificant findings of
underweight status in previous studies of COVID-19
due to the small number of patients [13–17]. A large
study from Mexico of 51,633 COVID-19 patients
showed those with obesity had higher risks of hospi-
talization, intensive care unit (ICU) admission and
intubation [24]. Another cohort study from the United
Kingdom involving 20,133 patients also found obesity
to be a risk factor of death [25]. Underweight patients
were not investigated in either study. A recent cohort
study conducted in South Korea and published in
December 2020 emphasized the increased mortality of
underweight patients [26]. However, the study was
designed to include patients under the age of
20 years, and such patients cannot be classified
according to adult BMI criteria. To our knowledge,
there was only one death in the group of adult
patients under age 50, which was too small of a sam-
ple size to be analyzed (Supplementary Table 1).
Because the rate of mortality due to COVID-19 in
young patients is extremely low, and sporadic out-
breaks have occurred in nursing homes in South
Korea, we identified a need for further research
focussed on older populations to help predict the
prognosis of COVID-19. Herein, we conducted a
nationwide cohort study to determine the effect of
BMI on the severity and mortality of COVID-19 among
older patients in Korea.
Methods
Data sources
Cohort data containing inpatient records of South
Korean COVID-19 patients were released by the
Central Disease Control Headquarters of the Korea
Centres for Disease Control and Prevention. COVID-19
was defined by a positive result on a real-time reverse
transcription-polymerase chain reaction (rRT-PCR)
assay for SARS-CoV-2 with an upper respiratory tract
specimen, with or without a positive result with a
lower respiratory tract specimen. Data were collected
by the patient information management office, the
Korean Health Information Management Association
and the National Medical Centre. Patients who were
admitted to a hospital and released from quarantine
between 20th January and 30th April 2020, were
included. Patients were released from quarantine after
complete recovery, which was defined by two con-
secutive negative PCR results with at least a 24-h
interval between them. Data on age, sex, survival sta-
tus, maximum disease severity, ICU admission, length
of stay until release from quarantine or death, BMI,
review of the system, initial vital signs, laboratory test
results and comorbidities were obtained. Age was
categorized into 10-year intervals. Maximum disease
severity during admission was divided into 8 catego-
ries: no limit of activity, the limit of activity without
oxygen, oxygen via nasal cannula, oxygen via a facial
mask, non-invasive ventilation, invasive ventilation,
multiorgan failure or extracorporeal membrane oxy-
genation (ECMO) and death.
Study population
Data were collected from 5628 patients. Patients
under 60 years of age and those with missing BMI
data were excluded from the study because the mor-
tality rate in patients under the age of 60 was
extremely low (0.3%). Even though the WHO definition
of older patients is 65 years or older, our data were
provided in age groups with 10-year intervals, and to
allow for convenient comparisons with previous stud-
ies, the cut-off of 60 years was deemed reason-
able [17].
Definitions of variables
BMI was calculated as the weight (kg) divided by the
squared height (m2) and categorized according to the
WHO Asian criteria into 5 categories: underweight
(<18.5 kg/m2), normal weight (18.5–22.9 kg/m2),
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overweight (23.0–24.9 kg/m2), class I obesity
(25.0–29.9 kg/m2), and class II obesity (30.0 kg/
m2) [19].
Outcomes
Our primary outcome was death before releasing from
quarantine, and the secondary outcome was a severe
infection. Severe infection was defined as the use of
invasive mechanical ventilation or the development of
multiorgan failure, the need for ECMO or death.
Study design and statistical analysis
This is a retrospective cohort study using the data
released by the Central Disease Control Headquarters
of Korea Centres for Disease Control and Prevention.
We described the characteristics of the given clinical
factors and their association with BMI. Univariable ana-
lysis of the factors and outcomes was performed by
Fisher’s exact test and the v2 test for categorical varia-
bles. Covariates included factors that were statistically
significant (p-value< .1) in the univariable analysis.
Stratified analysis was used to identify confounders
and effect modifiers. Multicollinearity was eliminated
by using the generalized variance inflation factor.
Multivariable logistic regression analysis was used and
adjusted for the selected covariates. The normal
weight group was set as a reference. Adjusted odds
ratios (aORs) and 95% confidence intervals (CIs) were
calculated, and a p-value< .05 was considered statis-
tically significant.
Most of the previous studies have set the reference
value as a BMI less than 25 kg/m2 due to the lack of
cases in the underweight group and because the
normal BMI standard of Westerners is 18.5–24.9 kg/m2.
We designed an additional analysis utilizing the WHO
standard criteria for BMI to make it easier to compare
our results with those of existing studies. All statistical
analyses were performed by R, version 4.0.2 (www.R-
project.org).
Ethical statement
The study was approved by the Hanyang University
Institutional Review Board (HYUH 2020-07-037). The
need to obtain informed consent was waived by the
Institutional Review Board.
Results
Characteristics of the study population
A total of 5628 COVID-19 patients were hospitalized
and released from quarantine. A total of 3182 patients
under the age of 60 and 1202 patients with missing
BMI data were excluded. The final study population
comprised 1,272 patients (60 years old) (Figure 1).
The majority of the underweight (61.2%) and normal-
weight patients (64.8%) were female, and the under-
weight group had the highest percentage of deaths
and severe infections (22.7%). Cough was the most
common symptom overall (43.7%). Hypertension was
the most common comorbidity among older COVID-19
patients (44.8%). DM had the highest prevalence in
the class I obesity group (29.8%), and dementia was
most common in underweight patients (29.9%)
(Table 1).
COVID-19 patients (n=5,628) 
2020.01.20 ~ 2020.04.30 
Final inclusion of 
older COVID-19 patients ( 60 years old) 
(n=1,272) 
Exclusion criteria (n=4,356) 
- Age 0-59 years (n=3,182) 
- Missing BMI (n=1,202) 
Figure 1. Flow chart of the study population. Definition of abbreviations: COVID-19: coronavirus disease 2019; BMI: body
mass index
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Univariable analysis
The number of patients aged 80 years or older was the
lowest (16.5%), but this group had the highest number
of deaths (48.7%). The majority of the patients were in
the normal weight group (38.4%), and the class II obes-
ity group had the lowest percentage of patients (2.4%).
We considered p-values <.1 statistically significant.
Univariable analysis showed that sex, diabetes mellitus
(DM), hypertension (HTN), heart disease, lung disease,
chronic kidney disease (CKD), cancer, and dementia
were associated with the outcomes (Table 2). Vital signs
and symptoms were not included because they are con-
sidered mediator variables rather than covariates.
Multivariable analysis
Multivariable logistic regression adjusted for the cova-
riates is shown in Table 3. The underweight group
had a 2.23-fold higher risk (95% CI, 1.06–4.52) of death
than the normal weight group. The overweight group
showed a lower risk of death, with an aOR of 0.50
(95% CI, 0.27–0.91), and classes I and II obesity were
not significantly associated with the risk of death. The
male population had a 2.28-fold higher mortality risk
(95% CI, 1.49–3.52) than the female population. DM,
HTN, CKD, cancer, and dementia were associated with
a higher risk of death. Dementia had the highest aOR
of 5.55 (95% CI, 3.28–9.33).




p-Value<18.5 (n¼ 67) 18.5–22.9 (n¼ 488) 23.0–24.9 (n¼ 360) 25.0–29.9 (n¼ 326) 30 (n¼ 31)
Age (years) <.001
60–69 684 (53.8) 17 (25.4) 251 (51.4) 207 (57.5) 190 (58.3) 19 (61.3)
70–79 378 (29.7) 28 (41.8) 136 (27.9) 111 (30.8) 95 (29.1) 8 (25.8)
80 210 (16.5) 22 (32.8) 101 (20.7) 42 (11.7) 41 (12.6) 4 (12.9)
Sex
Female 750 (59.0) 41 (61.2) 316 (64.8) 198 (55.0) 171 (52.5) 24 (77.4) .001
Male 522 (41.0) 26 (38.8) 172 (35.2) 162 (45.0) 155 (47.5) 7 (22.6)
Outcome
Severe infection† (N/A¼ 9) 136 (10.7) 15 (22.7) 52 (10.7) 23 (6.4) 41 (12.7) 5 (16.1) .001
Death 117 (9.2) 15 (22.7) 46 (9.5) 18 (5.0) 35 (10.9) 3 (9.7) <.001
ICU (N/A¼ 8) 106 (8.3) 6 (9.0) 33 (6.8) 27 (7.5) 35 (10.9) 5 (16.1) .137
Vital sign
SBP (mmHg) (N/A¼ 1) .001
<120 213 (16.7) 21 (31.3) 97 (19.9) 49 (13.6) 42 (12.9) 4 (12.9)
120–139 429 (33.7) 14 (20.9) 166 (34.1) 127 (35.3) 107 (32.8) 15 (48.4)
140 629 (49.4) 32 (47.8) 224 (46.0) 184 (51.1) 177 (54.3) 12 (38.7)
HR (beats/min) (N/A¼ 2) 81.0 (73.5–90.0) 81.0 (71.0–92.0) 82.0 (74.0–95.0) 85.0 (76.0–95.0) 80.0 (73.0–88.0) .004
Temp. (C) (N/A¼ 3) 36.8 (36.5–37.3) 36.8 (36.5–37.4) 36.8 (36.5–37.2) 36.9 (36.5–37.3) 37.0 (36.7–37.3) .262
ROS (N/A¼ 1)
Fever 337 (26.5) 18 (26.9) 134 (27.5) 91 (25.3) 87 (26.7) 7 (22.6) .944
Cough 556 (43.7) 32 (47.8) 201 (41.2) 160 (44.4) 147 (45.1) 16 (51.6) .587
Sputum 415 (32.6) 24 (35.8) 156 (32.0) 118 (32.8) 107 (32.8) 10 (32.3) .981
Sore throat 144 (11.3) 7 (10.4) 47 (9.6) 46 (12.8) 41 (12.6) 3 (9.7) .593
Rhinorrhea 99 (7.8) 6 (9.0) 38 (7.8) 27 (7.5) 24 (7.4) 4 (12.9) .847
Myalgia 191 (15.0) 4 (6.0) 80 (16.4) 55 (15.3) 48 (14.7) 4 (12.9) .270
Fatigue 74 (5.8) 2 (3.0) 32 (6.6) 21 (5.8) 18 (5.5) 1 (3.2) .754
Shortness of breath 251 (19.7) 13 (19.4) 88 (18.0) 64 (17.8) 78 (23.9) 8 (25.8) .191
Headache 161 (12.7) 4 (6.0) 71 (14.5) 46 (12.8) 38 (11.7) 2 (6.5) .225
Altered mentality 13 (1.0) 1 (1.5) 8 (1.6) 0 (0.0) 4 (1.2) 0 (0.0) .188
Nausea/Vomiting 75 (5.9) 4 (6.0) 33 (6.8) 22 (6.1) 15 (4.6) 1 (3.2) .722
Diarrhea 97 (7.6) 1 (1.5) 42 (8.6) 27 (7.5) 26 (8.0) 1 (3.2) .271
Comorbidity
DM 332 (26.1) 14 (20.9) 111 (22.7) 102 (28.3) 97 (29.8) 8 (25.8) .137
HTN 570 (44.8) 23 (34.3) 178 (36.5) 167 (46.4) 183 (56.1) 19 (61.3) <.001
Heart Dz (N/A¼ 4) 127 (10.0) 8 (11.9) 39 (8.0) 37 (10.3) 41 (12.6) 2 (6.5) .260
Lung Dz 61 (4.8) 7 (10.4) 19 (3.9) 16 (4.4) 16 (4.9) 3 (9.7) .122
CKD 26 (2.0) 1 (1.5) 11 (2.3) 5 (1.4) 7 (2.1) 2 (6.5) .405
Cancer (N/A¼ 1) 53 (4.2) 3 (4.5) 27 (5.5) 9 (2.5) 11 (3.4) 3 (9.7) .106
Liver Dz (N/A¼ 40) 27 (2.1) 3 (4.5) 8 (1.7) 5 (1.4) 10 (3.2) 1 (3.3) .315
RDAD (N/A¼ 41) 12 (0.9) 0 (0.0) 9 (1.9) 2 (0.6) 1 (0.3) 0 (0.0) .128
Dementia (N/A¼ 41) 117 (9.2) 20 (29.9) 62 (13.1) 20 (5.7) 15 (4.8) 0 (0.0) <.001
All categorical variables are given in numbers (percentage). Percentages may not total to 100 due to rounding. Continuous nonparametric variables are
given as the median (IQR). A Chi-square test or Fisher’s exact test was used for categorical variables. The Mann–Whitney U test was used for continuous
nonparametric variables (p-value < .1 is statistically significant).
Severe infection†: outcome of invasive mechanical ventilation, extracorporeal membrane oxygenation, multiorgan failure or death.
Definition of abbreviations: BMI: body mass index; N/A: not available; ICU: intensive care unit; SBP: systolic blood pressure; HR: heart rate; Temp: tem-
perature; ROS: review of system; DM: diabetes mellitus; HTN: hypertension; Dz: disease; CKD: chronic kidney disease; RDAD: rheumatic disease/auto-
immune disease; IQR: interquartile range.
ANNALS OF MEDICINE 1295
With regard to severe infection, the underweight
group and the normal weight group did not signifi-
cantly differ. The overweight group had a lower risk of
severe infection, with an aOR of 0.55 (95% CI,
0.31–0.94). Male sex, DM, HTN, heart disease, CKD,
cancer, and dementia were associated with a higher
risk of severe infection.
The results according to the WHO BMI criteria
are given in Supplementary Table 2. The BMI <
18.5 kg/m2 group had a higher risk of death (aOR,











Age (years) <.001 <.001
60–69 684 (53.8) 28 (20.6) 647 (57.4) 18 (15.4) 666 (57.7)
70–79 378 (29.7) 49 (36.0) 329 (29.2) 42 (35.9) 336 (29.1)
80 210 (16.5) 59 (43.4) 151 (13.4) 57 (48.7) 153 (13.2)
Sex <.001 .001
Female 750 (59.0) 56 (41.2) 691 (61.3) 51 (43.6) 699 (60.5)
Male 522 (41.0) 80 (58.8) 436 (38.7) 66 (56.4) 456 (39.5)
ICU (N/A¼ 8) 106 (8.3) 66 (48.5) 40 (3.5) <.001 54 (46.2) 52 (4.5) <.001
BMI (kg/m2) .001 <.001
<18.5 67 (5.3) 15 (11.0) 51 (4.5) 15 (12.8) 15 (12.8)
18.5–22.9 488 (38.4) 52 (38.2) 434 (38.5) 46 (39.3) 46 (39.3)
23.0–24.9 360 (28.3) 23 (16.9) 335 (29.7) 18 (15.4) 342 (29.6)
25.0–29.9 326 (25.6) 41 (30.1) 281 (24.9) 35 (29.9) 291 (25.2)
30.0 31 (2.4) 5 (3.7) 26 (2.3) 3 (2.6) 28 (2.4)
Comorbidity
DM 332 (26.1) 58 (42.6) 272 (24.1) <.001 52 (44.4) 280 (24.2) <.001
HTN 570 (44.8) 85 (62.5) 483 (42.9) <.001 73 (62.4) 497 (43.0) <.001
Heart Dz (N/A¼ 4) 127 (10.0) 25 (18.4) 102 (9.1) .001 21 (17.9) 106 (9.2) .005
Lung Dz 61 (4.8) 13 (9.6) 48 (4.3) .012 12 (10.3) 49 (4.2) .007
CKD 26 (2.0) 11 (8.1) 15 (1.3) <.001 9 (7.7) 17 (1.5) <.001
Cancer (N/A¼ 1) 53 (4.2) 12 (8.8) 41 (3.6) .009 12 (10.3) 41 (3.6) .001
Liver Dz (N/A¼ 40) 27 (2.1) 3 (2.2) 24 (2.2) 1.000 3 (2.6) 24 (2.2) 1.000
RDAD (N/A¼ 41) 12 (0.9) 1 (0.7) 11 (1.0) 1.000 1 (0.9) 11 (1.0) 1.000
Dementia (N/A¼ 41) 117 (9.2) 34 (25.0) 83 (7.6) <.001 34 (29.1) 83 (7.5) <.001
All categorical variables are given in numbers (percentage). Percentages may not total to 100 due to rounding. A chi-square test or Fisher’s exact test
was used for categorical variables. p-Value <.1 is statistically significant.
Severe infection†: outcome of invasive mechanical ventilation, extracorporeal membrane oxygenation, multiorgan failure or death.
Definition of abbreviations: BMI: body mass index; ICU: intensive care unit; N/A: not available; SBP: systolic blood pressure; HR: heart rate; Temp: tem-
perature; ROS: review of system; DM: diabetes mellitus; HTN: hypertension; Dz: disease; CKD: chronic kidney disease; RDAD: rheumatic disease/auto-
immune disease; IQR: interquartile range.
Table 3. Multivariable logistic regression results for risk of severe infection† and death in COVID-19 patients aged 60 years
or older.
Severe infection† Death
Adjusted OR 95% CI Adjusted OR 95% CI
BMI (kg/m2)
<18.5 1.99 0.96–3.96 2.23 1.06–4.52
18.5–22.9 Reference Reference
23.0–24.9 0.55 0.31–0.94 0.50 0.27–0.91
25.0–29.9 1.13 0.70–1.83 1.13 0.68–1.89
30.0 1.86 0.56–5.16 1.15 0.25–3.77
Sex
Female Reference Reference
Male 2.61 1.76–3.93 2.28 1.49–3.52
Comorbidity
DM 1.72 1.15–2.58 1.94 1.26–2.98
HTN 1.94 1.29–2.94 1.96 1.27–3.06
Heart Dz (N/A¼ 4) 1.78 1.04–2.96 1.69 0.94–2.92
Lung Dz 1.91 0.89–3.86 2.13 0.96–4.41
CKD 4.45 1.73–11.17 3.55 1.30–9.20
Cancer (N/A¼ 1) 2.68 1.26–5.38 3.54 1.65–7.17
Dementia (N/A¼ 41) 4.55 2.72–7.55 5.55 3.28–9.33
Logistic regression was used to determine odds ratio. The 95% confidence interval was used to determine statistical significance.
Severe infection†: outcome of invasive mechanical ventilation, extracorporeal membrane oxygenation, multiorgan failure or death.
Definition of abbreviations: COVID-19: coronavirus disease 2019; OR: odds ratio; CI: confidence interval; BMI: body mass index; DM: diabetes mellitus;
HTN: hypertension; Dz: disease; CKD: chronic kidney disease; N/A: not available.
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2.79; 95% CI, 1.35–5.54) and severe infection
(aOR, 2.44; 95% CI, 1.19–4.76) than the BMI
18.5–24.9 kg/m2 group. Groups of 25.0–29.9 kg/m2
and 30 kg/m2 did not show any statistical
significance.
Discussion
Our results showed that older COVID-19 patients with
a BMI under 18.5 kg/m2 had a higher risk of death
than those in the normal BMI group. This result was
not reported in most of the Western population-based
studies, in which the numbers of underweight patients
were small [13,17]. Our study had 67 underweight
patients out of 1272 patients with confirmed cases of
COVID-19 (5.3%), which was a higher proportion than
those in most of the studies on BMI and COVID-19
published to date. A recent large cohort study of 6.9
million people in England in which 3% of the patients
were underweight and 8.0% were of Asian ethnicity, a
J-shaped association between BMI and death due to
COVID-19 was identified, indicating an increased risk
of death in people with BMI 20 kg/m2 or less, which
supports our findings. However, the age-modified ana-
lysis showed an increased risk of death associated
with increasing BMI, which could not show the rela-
tionships of the risk of death with underweight and
overweight in older patients [27]. In our study, we
identified BMI as an independent prognostic factor of
death and severe infection in older COVID-19 patients.
Many previous studies have investigated the rela-
tionships between BMI and the incidence and mortal-
ity of various diseases [28–37]. According to a cohort
study conducted in Denmark, the risk of infectious dis-
ease associated with BMI showed a U-shaped relation-
ship, indicating a higher risk in underweight patients,
especially for upper and lower respiratory infections
[28]. The reasons underlying the increased risk associ-
ated with obesity have been reported, but the explan-
ation for the increased risk associated with
underweight is still under debate. While studies have
shown that underweight increases all-cause mortal-
ity[10,30–32], some researchers have indicated that
this is a bias caused by reverse causation [33–38].
However, several studies have shown that under-
weight is an independent risk factor after accounting
for the potential for reverse causation [30,37–39].
There are several hypotheses regarding why under-
weight individuals have poor prognoses after contract-
ing infectious diseases. For example, problems with
the secretion of lymphocytes, albumin, and cytokines
during periods of malnutrition and secretion of leptin
in the context of sepsis [40–42]. By adjusting for fac-
tors that can be associated with reverse causation,
such as sex and dementia, we found that underweight
is independently associated with an increased risk of
death, while overweight is actually associated with
reduced risks of death and severe infection.
Although an attempt was made to include all pos-
sible confounders, information on smoking, ethnicity,
concomitant infections and socioeconomic status was
not available. Smoking is known to be a potential con-
founder of the risk of death in underweight patients
[37,43]. However, some studies observed similar pat-
terns regardless of smoking status [30,39,44]. A study
by Williamson et al., which linked 17,278,392 adult
patients from a registered health platform in England
with 10,926 COVID-19-related deaths found a hazard
ratio for mortality among current smokers of 0.89
(95% CI, 0.82–0.97), after full adjustment by other con-
founders. When adjusted for only demographic fac-
tors, a nonsignificant result was obtained, suggesting
the effect of smoking on the outcomes of COVID-19
may not be as substantial as previously believed [45].
However, the lack of this information is a major limita-
tion of our study. The results of some previous studies
have suggested that non-white ethnicity is a risk fac-
tor for death in COVID-19 patients [45,46]. Ethnicity
was missing from our data, which may have affected
the validity of the results. However, the percentage of
foreigners in Korea in 2019 was 3.4% according to
Statics Korea, and the majority of them were Asian
[47]. Unlike in other multiethnic countries, this con-
founder is unlikely to have caused bias.
Socioeconomic variables (i.e. education level, occupa-
tion, residence) have also been considered as potential
confounders in studies involving BMI [44,48]. However,
in order to enable everyone to access all preventive
measures regarding COVID-19, testing and treatment
costs for patients in Korea have been covered by the
National Health Insurance Service or government
funding. Although the adjustment was incomplete,
the provision of financial support means that these
missing factors are relatively less critical.
There are several possible explanations for the
results observed in older underweight and overweight
patients in our study. The nutritional status of older
patients in the underweight group was poor, and a
protective role played by cholesterol in obese patients
has been suggested. A previous meta-analysis showed
that mortality in patients aged 60 years or older was
reduced when their low-density lipoprotein level was
high [49]. Another explanation of the increased mor-
tality in underweight patients is the fat distribution.
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Obesity has been well studied as a major risk factor
for cardiometabolic diseases. Interestingly, researchers
have identified an even higher risk in some people
with normal weight who have a higher visceral fat
mass percentage and a lower gluteofemoral fat mass
percentage. This suggests that not only the amount of
fat mass but also its distribution can help predict the
prognosis in patients with various diseases [50].
Considering the fact that the proportion of intraabdo-
minal fat increases with age, the fat distribution in the
older population could explain their poor prognosis
[51]. The severity of COVID-19 and visceral obesity
have been shown to be associated in several studies
as well [52–54]. Because the findings have been based
upon small numbers of patients, further research is
needed to reveal whether the fat distribution is a bet-
ter predictor of severe COVID-19 than overall obesity.
Our multivariable analysis did not show any signifi-
cant associations of class I and II obesity with severe
infection or death. This finding is contrary to the pre-
vious major studies. This is because only 3 deaths
occurred in the BMI 30 kg/m2 group, and the
released data categorized individuals with a BMI
30 kg/m2 into a single group. In previous studies in
Western populations, the risk of mortality was the
highest in the severely obese group (BMI  35 kg/m2),
and severe obesity is not common in Korea
[2,13,14,17,55]. However, research by Kim et al. with
the same cohort data showed that BMI 25 kg/m2
was associated with a higher risk of death and high
morbidity in patients aged 50 years or older. High
morbidity was defined as the administration of oxygen
via nasal cannula or facial mask, non-invasive ventila-
tion, invasive ventilation, multiorgan failure/ECMO,
and death. The result of overweight showed no signifi-
cance, which is also different from the results of our
study [26].
Lower risks of both death and severe infection in
overweight patients are not novel findings. Previous
studies regarding BMI in older individuals have shown
that a higher BMI is associated with a reduction in
mortality or morbidity. Despite the arguments about
survivor bias and reverse causation affecting these
findings, the protective effect of overweight in older
adults is still a widely accepted concept [44,48,51].
Another study on BMI and all-cause mortality in
Koreans showed that individuals with a BMI of
23.0–24.9 kg/m2 had the lowest risk of death. Among
patients with respiratory diseases, a lower BMI was
associated with a higher risk of death [30]. This phe-
nomenon called the “obesity paradox”, is not fully
understood [56]. Whether COVID-19 adheres to the
“obesity paradox” has not yet been revealed, and
there have been many reports that obesity increases
the risk of death in COVID-19 patients. This finding
may be due to the unique characteristics of the pan-
demic, including the shortages of staff and equipment
[57]. Further studies are needed to clarify this matter.
This study has limitations. First, it is a retrospective
study based on already collected data. Due to the
nature of retrospective studies, it is impossible to com-
pletely control for missing data and confounding vari-
ables. A total of 1202 patients with missing BMI values
were excluded from our study. The characteristics of
the group of patients with missing data did not sig-
nificantly differ from those of the study group, except
for age, sex, DM, HTN and dementia (Supplementary
Table 3). The patient information was collected from
multiple centres, and the intention of this study was
not to identify an association between BMI and
COVID-19. Therefore, the missing data were omitted
randomly, without any intentionality. Although it is
not strongly suspected, the possibility of unchecked
BMI at certain centres may have resulted in selection
bias from data missing at random [58]. An overview of
the missing data for potentially confounding variables
has been provided above. Second, we were not able
to accurately assess the patients who received invasive
mechanical ventilation. Given that the variable was
the maximum clinical severity, it is unknown whether
the patients who died were on invasive mechanical
ventilation. To correct this problem, a definition of
severe infection was provided for this study. However,
the inability to accurately identify the association
between invasive mechanical ventilation and obesity,
which has been found to be very strong, remains a
limitation of this study [15,16]. Third, the numbers of
cases and mortality due to COVID-19 in Korea are
remarkably low compared to those in other countries.
Although large-scale nationwide cohort data were
used and statistically significant results were derived,
the results had wide confidence intervals due to the
low mortality rate. Fourth, this study only included
hospitalized patients. However, unlike in many other
countries, a shortage of beds was not a major issue in
Korea, and most of the patients with confirmed cases
of COVID-19 were referred to the hospitals for admis-
sion until the treatment centre for mild or asymptom-
atic patients opened on 2nd March 2020. This may
have caused a potential bias due to the lack of data
from the patients who were not hospitalized, although
not great in number. Finally, this is a single-country
study, so it may have limits in its application to Asians
or individuals of other ethnicities.
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In conclusion, underweight is a risk factor for death
and overweight acts as a protective factor against
death and severe infection in older Korean COVID-19
patients. The optimal BMI advised for older COVID-19
patients should be 23.0–24.9 kg/m2 to lower the risk
of severe COVID-19 infection, and patients with BMI
values under 18.5 kg/m2 should be observed and
treated carefully.
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